Baidu
map

Diabetes Care:糖尿病增加维持性透析患者死亡风险

2013-06-13 Diabetes Care dxy

为了评价终末期肾脏疾病(ESRD)患者开始进行长期透析疗法后与糖尿病(DM)和新发DM有关的预测因子和危险因素,来自台湾奇美医学中心内科内分泌和代谢的田凯仁博士及其团队进行了一项研究(Epidemiology and mortality of new-onset diabetes mellitus after dialysis),研究发现,在维持性透析患者中,已有DM和新发DM均与长期死亡率增高相

为了评价终末期肾脏疾病(ESRD)患者开始进行长期透析疗法后与糖尿病(DM)和新发DM有关的预测因子和危险因素,来自台湾奇美医学中心内科内分泌和代谢的田凯仁博士及其团队进行了一项研究(Epidemiology and mortality of new-onset diabetes mellitus after dialysis),研究发现,在维持性透析患者中,已有DM和新发DM均与长期死亡率增高相关。研究结果在线发表于2013年5月30日的美国《糖尿病治疗》(Diabetes Care)杂志上,该杂志的影响因子为8.087。

研究人员对台湾全国健康保险研究资料库中1999年到2005年间开始接受透析疗法的ESRD患者的记录进行评价。随访病人时间从最初的透析疗法开始时间直至患者死亡、行移植手术、停止透析或直到2008年12月31日。新发DM和死亡率预测因子采用Cox比例风险模型计算。

结果显示,研究总共评价了51,487名接受透析疗法的患者,包括25,321名已有糖尿病患者、3,346名新发DM患者和22,820名非DM患者。三组患者平均年龄分别为61.8±11.5,61.6±13.7和56.5±16.6岁。第1年和第9年时,新发DM累积发病率分别为4%和21%。透析模式不是新发DM的危险因素(新发DM患者腹膜透析与血液透析风险比[HR]为0.94 [95% CI 0.83-1.06])。已有糖尿病与死亡风险增高80%相关(HR 1.81[95% CI 1.75-1.87]),而新发DM与死亡风险增高10%相关(HR 1.10[95% CI 1.03-1.17])。

研究表明,在维持性透析患者中,已有DM和新发DM均与长期死亡率增高相关,而透析模式与新发DM没有相关性。

Epidemiology and Mortality of New-Onset Diabetes Mellitus After Dialysis: Taiwan national cohort study.
Abstract
OBJECTIVEWe examined the predictors and risks associated with pre-existing versus new-onset diabetes mellitus (DM) after initiation of chronic dialysis therapy in end-stage renal disease (ESRD) patients.RESEARCH DESIGN AND METHODSIn the Taiwan National Health Insurance Research Database, we examined records of ESRD patients who initiated dialysis between 1999 and 2005. Patients were followed until death, transplant, dialysis withdrawal, or 31 December 2008. Predictors of new-onset DM and mortality were calculated using Cox models.RESULTSA total 51,487 incident dialysis patients were examined in this study, including 25,321 patients with pre-existing DM, 3,346 with new-onset DM, and 22,820 without DM at any time. Patients' age (mean ± SD) was 61.8 ± 11.5, 61.6 ± 13.7, and 56.5 ± 16.6 years in pre-existing, new-onset DM, and without DM groups, respectively. The cumulative incidence rate of new-onset DM was 4% at 1 year and 21% at 9 years. Dialysis modality was not a risk factor for new-onset DM (peritoneal dialysis to hemodialysis hazard ratio [HR] of new onset DM, 0.94 [95% CI 0.83-1.06]). Pre-existing DM was associated with 80% higher death risk (HR 1.81 [95% CI 1.75-1.87]), whereas the new-onset DM was associated with 10% increased death risk (HR 1.10 [95% CI 1.03-1.17]).CONCLUSIONSWhereas dialysis modality does not appear to associate with new-onset DM, both pre-existing and new-onset DM are related to higher long-term mortality in maintenance dialysis patients.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1901109, encodeId=50cc190110908, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon May 19 08:13:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759305, encodeId=5ac01e593056d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun May 18 12:13:00 CST 2014, time=2014-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983412, encodeId=b0cd198341277, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Nov 06 05:13:00 CST 2013, time=2013-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636695, encodeId=683d1636695e5, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Oct 30 14:13:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255444, encodeId=e3b0125544465, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Jun 15 04:13:00 CST 2013, time=2013-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570573, encodeId=566615e05731a, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Sat Jun 15 04:13:00 CST 2013, time=2013-06-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1901109, encodeId=50cc190110908, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon May 19 08:13:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759305, encodeId=5ac01e593056d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun May 18 12:13:00 CST 2014, time=2014-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983412, encodeId=b0cd198341277, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Nov 06 05:13:00 CST 2013, time=2013-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636695, encodeId=683d1636695e5, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Oct 30 14:13:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255444, encodeId=e3b0125544465, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Jun 15 04:13:00 CST 2013, time=2013-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570573, encodeId=566615e05731a, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Sat Jun 15 04:13:00 CST 2013, time=2013-06-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1901109, encodeId=50cc190110908, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon May 19 08:13:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759305, encodeId=5ac01e593056d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun May 18 12:13:00 CST 2014, time=2014-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983412, encodeId=b0cd198341277, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Nov 06 05:13:00 CST 2013, time=2013-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636695, encodeId=683d1636695e5, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Oct 30 14:13:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255444, encodeId=e3b0125544465, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Jun 15 04:13:00 CST 2013, time=2013-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570573, encodeId=566615e05731a, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Sat Jun 15 04:13:00 CST 2013, time=2013-06-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1901109, encodeId=50cc190110908, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon May 19 08:13:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759305, encodeId=5ac01e593056d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun May 18 12:13:00 CST 2014, time=2014-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983412, encodeId=b0cd198341277, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Nov 06 05:13:00 CST 2013, time=2013-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636695, encodeId=683d1636695e5, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Oct 30 14:13:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255444, encodeId=e3b0125544465, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Jun 15 04:13:00 CST 2013, time=2013-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570573, encodeId=566615e05731a, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Sat Jun 15 04:13:00 CST 2013, time=2013-06-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1901109, encodeId=50cc190110908, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon May 19 08:13:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759305, encodeId=5ac01e593056d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun May 18 12:13:00 CST 2014, time=2014-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983412, encodeId=b0cd198341277, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Nov 06 05:13:00 CST 2013, time=2013-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636695, encodeId=683d1636695e5, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Oct 30 14:13:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255444, encodeId=e3b0125544465, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Jun 15 04:13:00 CST 2013, time=2013-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570573, encodeId=566615e05731a, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Sat Jun 15 04:13:00 CST 2013, time=2013-06-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1901109, encodeId=50cc190110908, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon May 19 08:13:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759305, encodeId=5ac01e593056d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun May 18 12:13:00 CST 2014, time=2014-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983412, encodeId=b0cd198341277, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Nov 06 05:13:00 CST 2013, time=2013-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636695, encodeId=683d1636695e5, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Oct 30 14:13:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255444, encodeId=e3b0125544465, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Jun 15 04:13:00 CST 2013, time=2013-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570573, encodeId=566615e05731a, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Sat Jun 15 04:13:00 CST 2013, time=2013-06-15, status=1, ipAttribution=)]

相关资讯

JCEM:二甲双胍可抑制分化型甲状腺癌生长

临床试验显示二甲双胍增加癌症患者系统性治疗的疗效。为了验证分化型甲状腺癌(DTC)常规治疗的疗效在糖尿病患者中是否受到二甲双胍治疗的影响,来自美国国防医科大学的Vasyl Vasko教授及其团队进行了一项研究,该研究发现在肿瘤比较小的患者使用二甲双胍治疗,提示通过二甲双胍可抑制肿瘤生长。在糖尿病患者中,缺少二甲双胍治疗是完全缓解(CR)可能性减少和无进展生存期缩短风险增加的独立因素。体外数据提示在

JAMA:胃旁路手术治疗2型糖尿病:风险与获益并存

  美国和中国台湾联合研究表明,轻至中度肥胖的2型糖尿病患者,在改善生活方式和应用药物治疗的同时,行胃旁路手术,与较好的代谢转归相关。但临床应用时必须权衡附加胃旁路手术的潜在获益与严重不良事件风险。该论文6月5日发表于《美国医学会杂志》。   研究纳入120例糖尿病患者,所有患者糖化血红蛋白(HbA1c)≥8.0%,体质指数(BMI)为30.0~39.9,C肽>1.0 ng/ml,病程

JAMA:研究不支持减肥手术用于糖尿病非病态性肥胖成年患者

《美国医学会杂志》6月5日在线发表的一则综述研究对超过50项研究进行回顾,结果发现支持减肥手术治疗糖尿病或葡萄糖耐受性受损的非病态性肥胖成年患者(身体质量指数[BMI]30-35)的证据非常有限。就有关上述患者不多的有效数据而言,与药物治疗、饮食及行为干预等非手术介入措施相比,减肥手术与短期体重减轻、血糖浓度适度改善、血压及高胆固醇水平的较大改善有关。 “减肥手术常常被用于促进体重的减轻并被用于

Diabetes Care:低碳水化合物饮食可以保护肾功能

为了探讨各种饮食,特别是低碳水化合物高蛋白饮食,对有或没有2型糖尿病的患者肾功能的长期影响。来自以色列本古里安大学Iris Shai教授及其团队进行了一项研究,该研究发现在有或没有2型糖尿病、基线血清肌酐<176umol/l的中度肥胖患者中,低碳水化合物饮食与地中海饮食或低脂饮食在保护/改善肾功能方面一样安全。该研究结果在线发表在2013年5月20日的《糖尿病治疗》(Diabetes Care)杂

JCEM:血压与中风风险之间呈U字形相关

在糖尿病患者中,控制血压(BP)可以降低中风的风险;然而,在糖尿病患者中间,最低的中风风险的是否伴随最低的血压水平仍不清除。在路易斯安那州立大学以医院为基础纵向研究的糖尿病患者中间,为了探讨不同血压水平与中风风险之间的种族特异性关系,来自美国路易斯安那州彭宁顿生物医学研究中心的Gang Hu教授及其团队进行了一项研究,该研究发现血压与中风风险之间呈U字形相关,在非裔美国人和白人2型糖尿病患者中间,

BMC Endocr Disord:泌乳素与2型糖尿病患病率呈负相关

以往观察血清泌乳素浓度(PRL)与代谢综合征(MetS)和2型糖尿病(T2DM)的关系的研究都是在小型的、选择性研究样本,为了在大型基于人群的队列中,探讨血清泌乳素浓度与代谢综合征和2型糖尿病的潜在关系,来自德国格赖夫斯瓦尔德大学医学院的Robin Haring教授及其团队进行了一项研究,该研究发现在两种性别中,泌乳素都与2型糖尿病的流行之间呈横断面负相关。该研究结果发表在2013年5月的《英国医

Baidu
map
Baidu
map
Baidu
map